These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31305271)

  • 1. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
    Alhalabi O; Karam JA; Tannir NM
    Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Graham J; Bhindi B; Heng DYC
    Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization.
    Psutka SP; Kim SP; Gross CP; Van Houten H; Thompson RH; Abouassaly R; Weight C; Boorjian SA; Leibovich BC; Shah ND
    Urology; 2015 Feb; 85(2):442-50. PubMed ID: 25623717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.
    Mano R; Gopal N; Hakimi AA
    Curr Opin Urol; 2019 Sep; 29(5):531-539. PubMed ID: 31313716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
    Ghandour RA; Singla N; Margulis V
    Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
    Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
    Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now?
    Kokorovic A; Rendon RA
    Curr Opin Support Palliat Care; 2019 Sep; 13(3):255-261. PubMed ID: 31082942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors.
    Shapiro DD; Abel EJ
    Curr Opin Urol; 2019 Sep; 29(5):513-520. PubMed ID: 31305274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
    Hsiang WR; Kenney PA; Leapman MS
    Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
    Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
    World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.
    Smaldone MC; Handorf E; Kim SP; Thompson RH; Costello BA; Corcoran AT; Wong YN; Uzzo RG; Leibovich BC; Kutikov A; Boorjian SA
    J Urol; 2015 Apr; 193(4):1108-13. PubMed ID: 25444991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cytoreductive surgery in the era of targeted agents.
    Noe A; Stewart GD; Bex A
    Curr Opin Urol; 2015 Sep; 25(5):374-80. PubMed ID: 26075568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
    Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
    Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
    J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
    Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
    Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.